A prospective study evaluated tolerability and pharmacokinetics (PK) of two dosing regimens of LY-2944876 in healthy volunteers

Trial Profile

A prospective study evaluated tolerability and pharmacokinetics (PK) of two dosing regimens of LY-2944876 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Pegapamodutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Apr 2016 New trial record
    • 12 Mar 2016 Results (n=24) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top